NANOBIOTIX (EPA:NANO)

BRIEF

published on 12/17/2024 at 22:20, 3 days 20 hours ago

NANOBIOTIX Prepares its Revolutionary Virtual Event

Cancer NANOBIOTIX Curadigm Nanotherapeutic Technology Intravenous Medications
PRESS RELEASE

published on 12/17/2024 at 22:15, 3 days 20 hours ago

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
Nanobiotix announces virtual event 'Accelerating the Future of Nanotherapeutics' on December 19, 2024, showcasing Curadigm Nanoprimer Platform for drug development

Virtual Event NANOBIOTIX Curadigm Nanotherapeutics Nanoprimer
BRIEF

published on 12/09/2024 at 22:20, 11 days 20 hours ago

Nanobiotix successfully completes phase 1 study in pancreatic cancer

FDA Pancreatic Cancer Chemotherapy Phase 1 Study Radiotherapy
PRESS RELEASE

published on 12/09/2024 at 22:15, 11 days 20 hours ago

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
Nanobiotix completes Phase 1 study of NBTXR3 in pancreatic cancer, showing promising outcomes & safety profile. FDA approves new trial. Full data to be shared in 2025

FDA Approval Pancreatic Cancer NANOBIOTIX NBTXR3 Phase 1 Study
BRIEF

published on 11/25/2024 at 09:53, 26 days 8 hours ago

Threshold Crossing by Baillie Gifford at Nanobiotix

Voting Rights Capital Threshold Crossing NANOBIOTIX Baillie Gifford
BRIEF

published on 10/31/2024 at 08:35, 1 month 21 days ago

NANOBIOTIX to Participate in Investor Conferences in November

Innovation Investors Healthcare Conférences NANOBIOTIX
PRESS RELEASE

published on 10/31/2024 at 08:30, 1 month 21 days ago

NANOBIOTIX to Participate in Multiple Investor Conferences in November
Nanobiotix to participate in multiple investor conferences in November, including Guggenheim, Stifel, and Jefferies events to discuss innovative healthcare approaches

Investor Conferences Healthcare Innovation NANOBIOTIX Nanoparticle-based Approaches Late-stage Biotechnology
BRIEF

published on 10/11/2024 at 22:20, 2 months 9 days ago

Voting Rights and Share Capital Update by Nanobiotix

Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
PRESS RELEASE

published on 10/11/2024 at 22:15, 2 months 9 days ago

Voting Rights and Shares Capital of the Company
Nanobiotix discloses voting rights and shares capital information. Find out more about the company's innovative therapeutic approaches

Voting Rights Biotechnology Shares Capital NANOBIOTIX Therapeutic Approaches
BRIEF

published on 09/18/2024 at 22:20, 3 months 2 days ago

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

Revenue Increase Clinical Milestones Nanobiotix Financials NBTXR3 Progress Cash And Runway

1 2 ... 4

Published on 12/21/2024 at 01:30, 17 hours 14 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 14 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 18 hours 39 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 18 hours 44 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 19 hours 14 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 17 hours 53 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 17 hours 59 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 23 hours 34 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 23 hours 48 minutes ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 6 hours 27 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 4 hours ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE

News